Racial disparities in invasive streptococcus pneumoniae infections, 1998-2009

Clinical Infectious Diseases

Volumn 58, Issue 9, 2014, Pages 1250-1257

  Wortham, Jonathan M ^a   Zell, Elizabeth R ^b   Pondo, Tracy ^b   Harrison, Lee H ^c   Schaffner, William ^d   Lynfield, Ruth ^e   Thomas, Ann ^f   Reingold, Arthur ^g   Bennett, Nancy M ^h   Petit, Susan ⁱ   Aragon, Deborah ^j   Bareta, Joseph ^k   Juni, Billie A ^e   Farley, Monica M ^l,m   Beall, Bernard ^b   Moore, Matthew R ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e MINNESOTA DEPARTMENT OF HEALTH   (United States)

^f OREGON PUBLIC HEALTH DIVISION   (United States)

^g California Emerging Infections Program   (United States)

^h UNIVERSITY OF ROCHESTER   (United States)

ⁱ CDC   (United States)

^j Air Pollution Control Division   (United States)

^k Emerging Infections Program New Mexico Department of Health   (Mexico)

^l EMORY UNIVERSITY   (United States)

^m ATLANTA VA MEDICAL CENTER   (United States)

more..

Author keywords

continental population groups; pneumocccal vaccines; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE; PREVENAR13; VACCINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUCASIAN; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DISEASE SURVEILLANCE; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NEGRO; PNEUMOCOCCAL INFECTION; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; BLACK PERSON; EPIDEMIOLOGICAL MONITORING; ETHNOLOGY; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOGENICITY; SEROTYPING; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; EPIDEMIOLOGICAL MONITORING; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; VACCINES, CONJUGATE;

EID: 84898864818     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu108     Document Type: Article

References (29)

1. Flannery B, Schrag S, Bennett NM, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA 2004; 291:2197-203
2. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-35
3. Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated. MMWR Morb Mortal Wkly Rep 2008; 57:343-4
4. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-35
5. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46
6. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54:893-7
7. Tasslimi A, Sison EJ, Story E, et al. Disappearance of vaccine-Type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates. Clin Vaccine Immunol 2009; 16:1256-9
8. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008; 57:144-8
9. Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine 2011; 29:3398-412
10. US Department of Health and Human Services (DHHS). Healthy People 2020. Washington, DC: US Department of Health and Human Services, 2010
11. US Department of Health and Human Services. Healthy People 2010: Understanding and improving health. 2nd ed.Washington, DC: US Department of Health and Human Services, 2000
12. Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1-18
13. Ingram DD, Parker JD, Schenker N, et al. United States Census 2000 populations with bridged race categories. Vital Health Stat 2 2003; 135:1-55
14. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ: Wiley-Interscience, 2004
15. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: A gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59:1087-91
16. Park IH, MooreMR, Treanor JJ, et al. Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis 2008; 198:1818-22
17. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. Survey Methodology 2001; 27:85-95
18. US Department of Health and Human Services (DHHS). HHS action plan to reduce health disparities: A nation free of disparities in health and health care. Washington, DC: US Department of Health and Human Services, 2011
19. Ramakrishnan M, Moisi JC, Klugman KP, et al. Increased risk of invasive bacterial infections in African people with sickle-cell disease: A systematic review and meta-Analysis. Lancet Infect Dis 2010; 10:329-37
20. Muhammad RD, Oza-Frank R, Zell E, et al. Epidemiology of invasive pneumococcal disease among high-risk adults since the introduction of pneumococcal conjugate vaccine for children. Clin Infect Dis 2013; 56:e59-67
21. US Census Bureau. The 2009 American community survey. Washington: US Census Bureau, 2012
22. Burton DC, Flannery B, Bennett NM, et al. Socioeconomic and racial/ ethnic disparities in the incidence of bacteremic pneumonia among US adults. Am J Public Health 2010; 100:1904-11
23. Pilishvili T, Zell ER, Farley MM, et al. Risk factors for invasive pneumococcal disease in children in the era of conjugate vaccine use. Pediatrics 2010; 126:e9-17
24. Flory JH, Joffe M, Fishman NO, Edelstein PH, Metlay JP. Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 2009; 137:717-26
25. Kim PE, Musher DM, Glezen WP, Rodriguez-Barradas MC, Nahm WK, Wright CE. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis 1996; 22:100-6
26. Young GS, Fox MA, Trush M, Kanarek N, Glass TA, Curriero FC. Differential exposure to hazardous air pollution in the United States: A multilevel analysis of urbanization and neighborhood socioeconomic deprivation. Int J Environ Res Public Health 2012; 9:2204-25
27. Ho JY, Elo IT. The contribution of smoking to black-white differences in U.S. mortality. Demography 2013; 50:545-68
28. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681-9
29. US Department of Health and Human Services (DHHS), National Centerfor Health Statistics. The 2009 National Immunization Survey. Hyattsville, MD: US Centers for Disease Control and Prevention, 2010.